FDA approves new combination immunotherapy
Australian researchers and patients were critical to trialling this breakthrough new treatment for advanced melanoma patients.
Neoadjuvant therapy, a breakthrough in Stage III melanoma treatment
In what is being hailed as one of the biggest breakthroughs in melanoma treatment since the advent of immunotherapy, a new study has revealed that drug treatment before surgery is effective in preventing deadly spread of the disease.
MIA joins Sydney Health Partners
MIA has joined Sydney Health Partners, with a shared focus on more rapidly translating research evidence into patient benefit.
Congratulations Dr Hansol Lee
A promising young MIA researcher is conferred with University of Sydney PhD.
MIA research wins Cancer Institute of NSW ‘Wildfire Highly Cited Publication’
Cited an incredible 427 times around the world, showing its vital role in improving outcomes for people with advanced melanoma.
Prof Scolyer receives UTAS Alumni Award
The 'Distinguished Alumni Award' from University of Tasmania honours the exceptional impact of his work around the world.
Medical Directors receive USYD VC’s Award
The 'Outstanding Research Award' recognises their life-saving discoveries transforming melanoma patient care.
Prof Georgina Long awarded 2021 Ramaciotti Medal
The award recognises her pioneering work in immunotherapy in melanoma, transforming the care of patients worldwide.
MIA researchers on Highly Cited 2021 List
The highly anticipated annual list is the “who’s who” of the scientific elite from across the globe.
Skin surveillance saves lives from melanoma
New research shows routine skin checks by a health professional, plus checking your own skin, are vital in saving lives from melanoma.